Federal spending on Alzheimers disease-related programs in the Labor, Health and Human Services, Education and Related Agencies appropriations bill, including the National Institutes of Health, the Centers for Disease Control and Prevention and Federally-Qualified Health Centers
CMS policy on Medicare coverage of Alzheimer's disease treatments; Medicare policy on Alzheimer's disease early detection and intervention policies; H.R. 2408 - Access to Innovative Treatments Act of 2023; S. 133 - NAPA Reauthorization Act; S. 134 - Alzheimers Accountability and Investment Act
Duration: July 1, 2020
to
present
General Issues: Budget/Appropriations , Health Issues , Medical/Disease Research/Clinical Labs , Government Issues
Spending: about $1,240,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2020: House of Representatives, U.S. Senate, Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Niles Godes Chief of Staff, Sen. Byron Dorgan (D-ND); Democratic Staff Director, US Congress Joint Economic Committee
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, USAGAINSTALZHEIMERS ACTION did no lobbying for itself. The report was filed on April 18.
Original Filing: 301553132.xml
4th Quarter, 2023
In Q4, USAGAINSTALZHEIMERS ACTION did no lobbying for itself. The report was filed on Jan. 18.
Original Filing: 301527903.xml
3rd Quarter, 2023
In Q3, USAGAINSTALZHEIMERS ACTION did no lobbying for itself. The report was filed on Oct. 13, 2023.
Original Filing: 301500413.xml
2nd Quarter, 2023
In Q2, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301486482.xml
Lobbying Issues
Federal spending on Alzheimers disease-related programs in the Labor, Health and Human Services, Education and Related Agencies appropriations bill, including the National Institutes of Health, the Centers for Disease Control and Prevention and Federally-Qualified Health Centers
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS policy on Medicare coverage of Alzheimer's disease treatments; Medicare policy on Alzheimer's disease early detection and intervention policies; H.R. 2408 - Access to Innovative Treatments Act of 2023; S. 133 - NAPA Reauthorization Act; S. 134 - Alzheimers Accountability and Investment Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301464689.xml
Lobbying Issues
Federal spending on Alzheimers disease-related programs in the Labor, Health and Human Services, Education and Related Agencies appropriations bill, including the National Institutes of Health, the Centers for Disease Control and Prevention and Federally-Qualified Health Centers
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS policy on Medicare coverage of Alzheimer's disease treatments; Medicare policy on Alzheimer's disease early detection and intervention policies; H.R. 2408 - Access to Innovative Treatments Act of 2023; S. 133 - NAPA Reauthorization Act; S. 134 - Alzheimers Accountability and Investment Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301440287.xml
Lobbying Issues
Federal spending on Alzheimers disease-related programs in the Labor, Health and Human Services, Education and Related Agencies appropriations bill, including the National Institutes of Health, the Centers for Disease Control and Prevention and Federally-Qualified Health Centers; Fiscal Year 2023 Omnibus Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS policy on Medicare coverage of Alzheimer's disease treatments; Medicare policy on Alzheimers disease early detection and intervention policies; Establishment of an Advanced Research Projects Agency for Health; FDA accelerated approval pathway legislation.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on Oct. 18, 2022.
Original Filing: 301408319.xml
Lobbying Issues
Federal spending on Alzheimers disease-related programs in the Labor, Health and Human Services, Education and Related Agencies appropriations bill, including the National Institutes of Health, the Centers for Disease Control and Prevention and Federally-Qualified Health Centers.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS policy on early detection; Alzheimers disease early intervention policies; Establishment of an Advanced Research Projects Agency for Health; Providing CMS coverage for Alzheimers disease treatments.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on July 18, 2022.
Original Filing: 301383017.xml
Lobbying Issues
Federal spending on Alzheimers disease-related programs in the Labor, Health and Human Services, Education and Related Agencies appropriations bill, including the National Institutes of Health, the Centers for Disease Control and Prevention and Federally-Qualified Health Centers.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS policy on early detection; Alzheimers disease early intervention policies; Establishment of an Advanced Research Projects Agency for Health; Providing CMS coverage for Alzheimers disease treatments.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301369340.xml
Lobbying Issues
National Institutes of Health and Centers for Disease Control Alzheimers disease research funding; Labor, Health and Human Services, Education and Related Agencies appropriations bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS policy on early detection; Establishing a national Alzheimers disease prevention goal; Alzheimers disease early intervention policies; Establishment of an Advanced Research Projects Agency for Health; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination for Alzheimers treatments.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on Jan. 18, 2022.
Original Filing: 301326013.xml
Lobbying Issues
National Institutes of Health Alzheimers disease research funding; Labor, Health and Human Services, Education and Related Agencies appropriations bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS policy on early detection; Establishing a national Alzheimers disease prevention goal; Alzheimers disease early intervention policies; Establishment of an Advanced Research Projects Agency for Health.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301307751.xml
Lobbying Issues
National Institutes of Health Alzheimers disease research funding; Labor, Health and Human Services, Education and Related Agencies appropriations bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS policy on early detection; Establishing a national Alzheimers disease prevention goal; Alzheimers disease early intervention policies; Establishment of an Advanced Research Projects Agency for Health.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on July 20, 2021.
Original Filing: 301290481.xml
Lobbying Issues
National Institutes of Health Alzheimers disease research funding; Labor, Health and Human Services, Education and Related Agencies appropriations bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS policy on early detection; Establishing a national Alzheimers disease prevention goal; Alzheimers disease early intervention policies; Establishment of an Advanced Research Projects Agency for Health.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301264861.xml
Lobbying Issues
National Institutes of Health Alzheimers disease research funding, Labor, Health and Human Services, Education and Related Agencies appropriations bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS policy on early detection. Establishing a national Alzheimers disease prevention goal. Alzheimers disease early intervention policies.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on Jan. 21, 2021.
Original Filing: 301243016.xml
Lobbying Issues
National Institutes of Health Alzheimers disease research funding, H.R. 7617 - Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
COVID-19 testing in nursing homes; Direct HHS to collect and report comprehensive data on COVID-19 infections and deaths for those with Alzheimers; H.R. 2283, S. 1126 - Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding to support biomedical research and maintain clinical trial infrastructure; H.R. 7308, S. 4286 - Research Investment to Spark the Economy Act
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2020
In Q3, USAGAINSTALZHEIMERS ACTION had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301223890.xml
Lobbying Issues
National Institutes of Health Alzheimers disease research funding, H.R. 7617 - Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
COVID-19 testing in nursing homes; Direct HHS to collect and report comprehensive data on COVID-19 infections and deaths for those with Alzheimers; H.R. 2283, S. 1126 - Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding to support biomedical research and maintain clinical trial infrastructure; H.R. 7308, S. 4286 - Research Investment to Spark the Economy Act
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2020
USAGAINSTALZHEIMERS ACTION filed a lobbying registration on July 17, 2020 for in-house lobbying efforts, effective July 1, 2020.
Original Filing: 301192282.xml
Issue(s) they said they’d lobby about: Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019 - S. 1126, H.R. 2283; Labor, Health and Human Services, Education, and Related Agencies appropriations. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...